|Expense Ratio (net)||0.82%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Below Average|
|Beta (5Y Monthly)||1.00|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Apr 01, 1948|
Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.
NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESOTTAWA, ON, Feb. 23, 2021 /CNW/ - Tetra Bio-Pharma Inc.
23, 2021 /CNW/ - Trading resumes in: Company: Tetra Bio-Pharma Inc.TSX Symbol: TBP All Issues: YesResumption (ET): 8:00 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.